1. Home
  2. HUDI vs INAB Comparison

HUDI vs INAB Comparison

Compare HUDI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huadi International Group Co. Ltd.

HUDI

Huadi International Group Co. Ltd.

HOLD

Current Price

$0.42

Market Cap

10.0M

Sector

Industrials

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.99

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUDI
INAB
Founded
1998
2016
Country
China
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
11.8M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
HUDI
INAB
Price
$0.42
$0.99
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.00
AVG Volume (30 Days)
★ 322.5K
45.4K
Earning Date
06-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$0.88
52 Week High
$1.67
$2.73

Technical Indicators

Market Signals
Indicator
HUDI
INAB
Relative Strength Index (RSI) 15.42 39.42
Support Level N/A $0.92
Resistance Level $0.84 $1.22
Average True Range (ATR) 0.08 0.09
MACD -0.02 -0.03
Stochastic Oscillator 20.01 15.18

Price Performance

Historical Comparison
HUDI
INAB

About HUDI Huadi International Group Co. Ltd.

Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: